Risk factor
Considerable default risk
Profitability factor
Slightly undervalued vs peers
About
Acomo N.V., operating globally through its various subsidiaries, specializes in the procurement, commerce, transformation, packaging, and distribution of a wide array of conventional and organic foodstuffs and their constituent elements for the international food and beverage sector. The company's operations are organized into five primary divisions: Spices and Nuts, Edible Seeds, Organic Ingredients, Tea, and Food Ingredients. The Spices and Nuts segment offers an extensive selection of tropical items, including pepper, nutmeg, and desiccated coconut, alongside both shelled and unshelled nuts, dried fruits, dehydrated vegetables, culinary herbs, chocolate, rice crackers, and diverse snack products. Within its Edible Seeds division, Acomo provides various seeds for consumption, such as in-shell and hulled sunflower seeds, poppy seeds, sesame seeds, and other edible seed varieties. The Organic Ingredients segment delivers a broad spectrum of organic culinary products and components, covering numerous categories like cocoa, coffee, fresh produce, edible seeds, nuts, dried fruits, oils, and premium juices. The Tea division focuses on sourcing and supplying different tea products. Finally, the Food Ingredients segment manufactures and furnishes food manufacturing enterprises with a range of culinary and functional components, pre-mixed wet and dry blends, and bespoke spice formulations. Founded in 1819, the company officially changed its name to Acomo N.V. in June 2022, having previously been known as Amsterdam Commodities N.V. Its main corporate office is located in Rotterdam, the Netherlands.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/E
Target Price
The average target price of ACOMO.AS is 26 and suggests 15% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio